Givinostat is an oral small-molecule histone deacetylase (HDAC) inhibitor used to slow the progression of muscle degeneration in patients with Duchenne muscular dystrophy. By targeting HDAC6, the drug… Read more











Givinostat is an oral small-molecule histone deacetylase (HDAC) inhibitor used to slow the progression of muscle degeneration in patients with Duchenne muscular dystrophy. By targeting HDAC6, the drug helps preserve muscle integrity and reduce the accumulation of toxic protein aggregates. The Givinostat reference standards, impurities, and metabolites included in this category are essential for pharmaceutical laboratories conducting rigorous analytical testing and quality control. Researchers utilize these high-quality compounds for impurity profiling, method validation, and the development of stability-indicating assays. The selection includes specific degradation products, such as desethyl and nitroso derivatives, alongside relevant human metabolites like O-glucuronide conjugates. Additionally, stable isotope labelled versions of Givinostat and its impurities serve as critical internal standards for quantitative analysis, enabling precise tracking and identification in complex biological matrices during drug development and manufacturing processes.